https://www.selleckchem.com/pr....oducts/brensocatib.h
001). The bone age/chronological age (BA/CA) ratio did not differ significantly among ISS, GHD and SGA groups after GH therapy. The HtSDS gain was higher in children with GHD compared to other ISS, SGA and TS groups (p less then 0.01; p 0.015 and p 0.029, respectively). HtSDS improvement occurred during the first 3 years of rhGH therapy. The BMISDS increased significantly in children with GHD, after 3 years of rhGH therapy (p less then 0.001). After rhGH treatment, the BMISDS decreased significantly in children with ISS and SGA (p l
Like
Comment
Share
